Core Viewpoint - Teleflex reported a revenue of $749.69 million for the quarter ended June 2024, showing a year-over-year increase of 0.9% and an EPS of $3.42, slightly up from $3.41 a year ago, but below the Zacks Consensus Estimate of $763.39 million, resulting in a revenue surprise of -1.79% [1] Revenue Performance - Geographic Revenues in the Americas reached $426.80 million, slightly below the average estimate of $432.19 million, reflecting a year-over-year change of +0.5% [3] - Geographic Revenues in Asia totaled $87 million, marginally below the estimated $87.90 million, with a year-over-year increase of +0.4% [4] - Geographic Revenues in EMEA were reported at $147.10 million, significantly lower than the estimated $157.16 million, indicating a year-over-year decline of -0.5% [5] Segment Revenues - Net Revenues from Vascular Access were $181.10 million, close to the average estimate of $181.31 million, with a year-over-year increase of +4.2% [6] - Net Revenues from Interventional reached $141.20 million, exceeding the estimate of $137.89 million, marking a year-over-year growth of +13.1% [7] - Net Revenues from Anesthesia were reported at $102.50 million, slightly below the estimate of $104.01 million, with a year-over-year increase of +1.7% [8] - Revenues from OEM (Original Equipment Manufacturer and Development Services) were $88.80 million, surpassing the estimate of $88.27 million, reflecting a year-over-year increase of +5.6% [9] - Net Revenues from Interventional Urology were $83.10 million, slightly below the estimate of $83.48 million, with a year-over-year increase of +6.8% [10] - Net Revenues from Other segments were reported at $41.70 million, significantly below the estimate of $55.13 million, indicating a year-over-year decline of -45.1% [11] - Net Revenues from Surgical were $111.30 million, close to the estimate of $111.50 million, with a year-over-year increase of +5% [12] Stock Performance - Teleflex shares have returned +4.5% over the past month, outperforming the Zacks S&P 500 composite's +1.1% change, and the stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [12]

Teleflex (TFX) came out with quarterly earnings of $3.42 per share, beating the Zacks Consensus Estimate of $3.33 per share. This compares to earnings of $3.41 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 2.70%. A quarter ago, it was expected that this medical equipment maker would post earnings of $3.07 per share when it actually produced earnings of $3.21, delivering a surprise of 4.56%. Over the last four quarters, the c ...

WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 16, 2024, to shareholders of record at the close of business on August 15, 2024. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to ...

WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 16, 2024, to shareholders of record at the close of business on August 15, 2024. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to ...

WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the second quarter ended June 30, 2024. Second quarter financial summary GAAP revenue of $749.7 million, up 0.9% compared to the prior year period Adjusted revenue of $763.5 million, excluding the impact from increases in our reserves related to the Italian payback measure pertaining to prior years, up 2.7% compared to the prior year period, up 3.4% on a constant currency bas ...

Core Viewpoint - Analysts project that Teleflex will report quarterly earnings of $3.33 per share, reflecting a decline of 2.4% year over year, with revenues expected to reach $763.39 million, an increase of 2.7% from the same quarter last year [10] Revenue Estimates - 'Net Revenues- Anesthesia' is estimated to be $104.01 million, indicating a change of +3.2% from the year-ago quarter [2] - 'Geographic Revenues- EMEA' is expected to be $157.16 million, showing a change of +6.3% from the year-ago quarter [3] - 'Net Revenues- Interventional Urology' is projected at $83.48 million, reflecting a change of +7.3% from the prior-year quarter [5] - 'Net Revenues- Surgical' is forecasted to reach $111.50 million, indicating a change of +5.2% from the prior-year quarter [6] - 'Revenues- OEM (Original Equipment Manufacturer and Development Services)' is estimated at $88.27 million, suggesting a change of +5% year over year [8] - 'Geographic Revenues- Americas' is likely to reach $432.19 million, indicating a change of +1.8% year over year [9] - 'Net Revenues- Interventional' is estimated at $137.89 million, reflecting a change of +10.5% year over year [11] - 'Net Revenues- Other' is projected to be $55.13 million, indicating a change of -27.5% year over year [12] - 'Net Revenues- Vascular Access' is expected to reach $181.31 million, showing a year-over-year change of +4.3% [14] - 'Geographic Revenues- Asia' is forecasted to be $87.90 million, indicating a change of +1.4% from the year-ago quarter [15] Earnings Estimate Revisions - Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter, indicating that analysts have not changed their initial forecasts during this period [4] Stock Performance - Teleflex shares have experienced a change of +5.4% in the past month, compared to a -0.4% move of the Zacks S&P 500 composite, with a Zacks Rank 3 (Hold) suggesting that TFX is expected to mirror overall market performance in the near future [7]

The Ringer™ PBC is a rapid-exchange 0.014" compatible catheter with a unique helical balloon at its working end. When inflated, this balloon approximates a hollow cylinder with a large central perfusion lumen. These characteristics allow for continuous coronary blood flow during prolonged inflations.2 The Ringer™ PBC is indicated for balloon dilatation of coronary artery or coronary bypass graft stenoses where the physician desires distal blood perfusion during balloon inflation for the purpose of improving ...

WAYNE, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Ringer™ Perfusion Balloon Catheter (PBC), the only commercially available Percutaneous Transluminal Coronary Angioplasty (PTCA) perfusion balloon.1 "The Ringer PTCA Clinical Study demonstrated that inflation of the Ringer™ PBC for 60 seconds or more was well tolerated in the majority of patients who ...

QuikClot™ Hemostatic Dressings and Devices control bleeding faster than standard gauze or laparotomy pads,1-3 enabling clinicians to move patients to the next stage of care quickly. The portfolio includes a range of products to support clinicians throughout the hospital, including in the Emergency Department, Operating Room, Intensive Care Unit, and Catheterization Lab. Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers ...

Premier's SURPASS® program is designed to drive the highest-level commitment and savings for members through aggregated purchasing of high-quality products and services. The program brings together Premier's most committed members to coordinate purchasing decisions and maintain standardization across their facilities. By providing additional value to Premier contracted suppliers through volume and commitment, the program is expected to achieve best-in-market pricing. "QuikClot™ Hemostatic Dressings and the ...